GA
TLOG

Geneva Advisors’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Geneva Advisors’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-52,471
Closed -$9K – 765
2016
Q1 		$9K Buy
+52,471
New +$14.6K ﹤0.01% 694

Other funds holding TLOG

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Geneva Advisors's TLOG Position: Q2 2016 in Review

Geneva Advisors sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2016, closing a stake of 52,471 shares — an estimated $9K sold.

Geneva Advisors first reported a position in TLOG in Q1 2016 and held it in 1 quarter. The position peaked at $9K in Q1 2016. 19 funds tracked by Wall St. Rank hold TLOG as of Q2 2016.

  • Geneva Advisors reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2016 after selling out during the quarter.
  • Geneva Advisors sold 52,471 TetraLogic Pharmaceuticals Corporation shares in Q2 2016, an estimated $9K.
  • Geneva Advisors first reported a position in TetraLogic Pharmaceuticals Corporation in Q1 2016 and held it in 1 quarter.
  • Geneva Advisors's TetraLogic Pharmaceuticals Corporation position peaked at $9K in Q1 2016.
  • 19 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2016.

Based on Geneva Advisors's 13F filing for Q2 2016, filed 8 Aug 2016.